Form 4: ORIC CEO Sells Shares Under Pre-Arranged Plan

Oric Pharmaceuticals' President and CEO, Jacob Chacko, sold 37,461 shares of common stock for $12.32 per share under a Rule 10b5-1 trading plan.

Summary

• Jacob Chacko, President and CEO of Oric Pharmaceuticals, Inc. (ORIC), reported a sale of common stock.
• The transaction involved the disposition of 37,461 shares of ORIC common stock.
• The shares were sold at a weighted average price of $12.32 per share, with prices ranging from $12.07 to $12.59.
• The sale was executed on October 6, 2025, pursuant to a Rule 10b5-1 trading plan adopted on June 21, 2025.
• Following this transaction, Jacob Chacko directly beneficially owns 531,419 shares of common stock.
• Additionally, Jacob Chacko holds 178,667 restricted stock units (RSUs) and stock options to purchase 3,378,000 shares, which are not included in the reported common stock ownership.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, adverse information. It's a planned liquidity event.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, adverse information.

Negatives

• An insider sale, even if pre-planned, reduces the CEO's direct equity stake in the company.

Risks

• No specific risks were detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the execution of a pre-arranged trading plan.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• The transaction involves the sale of company stock by a key executive (President and CEO), which is considered an insider transaction.

Stakeholder Impact

• Shareholders may observe the CEO's reduction in direct share ownership, though the 10b5-1 plan context suggests it's a planned financial management decision rather than a signal about company performance.

Key Dates

Keywords

Oric Pharmaceuticals, ORIC, Jacob Chacko, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Biotechnology, Pharmaceuticals